Is Lilly's Post-Foundayo Stock Slide a Geopolitical Blip or a Sign of Launch Hurdles Ahead?
Eli Lilly's (LLY) shares slipped 2-5% in recent trading sessions despite the FDA's approval of Foundayo (orforglipron), its highly anticipated oral GLP-1 drug for obesity with no usage restrictions. Broader geopolitical tensions—cited as a market headwind—overrode the milestone, leaving investors questioning if this is mere noise or an early warning on commercial uptake. As Novo Nordisk (NVO) grapples with its own injectable dominance under siege, Lilly's fundamentals scream opportunity.
Foundayo Approval: A Game-Changer Ignored by Markets
The approval marks a pivotal win for Lilly in the $100B+ obesity market, where injectables like Novo's Wegovy and Lilly's own Zepbound have driven explosive demand. Unlike competitors requiring gradual dose escalation or refrigeration, Foundayo offers once-daily oral convenience without restrictions, potentially accelerating patient adoption. Pre-launch inventories have ballooned to $952M by Q3 2025 (up from $548M at year-end 2024), signaling Lilly's confidence in rapid rollout—expected in the US by mid-2026 alongside Medicare access expansions.
Yet, shares fell amid unrelated geopolitical jitters, with LLY down 4.6% over the past month and 8.5% YTD, trading at a forward P/E of 26.3x. This contrasts sharply with the company's 44.7% TTM revenue growth to implied annual run-rates exceeding $65B, fueled by incretin blockbusters. Q4 2025 revenue hit $19.3B (up massively YoY), with gross margins at 83.8% and EBITDA margins at 42.9%—a testament to pricing power and scale.
| Metric (TTM) | LLY | NVO |
|---|---|---|
| Market Cap | $902B | $161B |
| Revenue Growth | +44.7% | +6.2% |
| EPS Growth | +95.4% | +1.7% |
| Gross Margin | 83.8% | 81.0% |
| 1M Price Return | -4.6% | -21.9% |
| 1Y Price Return | +19.9% | -51.9% |
Novo's Defensive Posture: Cracks in the Injectable Armor
Novo Nordisk, long the obesity kingpin, faces direct threats from Foundayo's oral profile. Wegovy sales grew 17% in Q4 2025 but US growth slowed to -2%, with total obesity care up just 11% CER amid competition. NVO's shares have cratered 21.9% in the past month and 51.9% over the past year, reflecting market share erosion—US GLP-1 leadership for Ozempic flipped to rivals in 2025, per filings.
Novo's 2026 guidance is grim: sales growth -5% to -13% CER, hammered by price cuts, MFN agreements, and channel shifts. Free cash flow is pegged at DKK 35-45B, with capex at DKK 55B for capacity amid softening demand. Earnings highlights note Wegovy's US prescription lead lost early 2025, while international obesity sales surged 77%—but US is the battleground, where Foundayo could pill-ify adherence barriers.
Lilly's edge? Orforglipron's Phase 3 data showed superior weight loss (up to 15%+), with management touting it as a "priority" via National Priority Voucher for expedited review. Q3 2025 call emphasized $63-63.5B full-year revenue (midpoint raised), with 2026 at $80-83B (+25%). Pre-launch build-up in SEC filings (e.g., $1.5B inventories by Dec 2025) underscores launch readiness, even as Chugai royalties loom (mid-single to low-teens %).
Uptake Trajectory: Oral vs. Needle Phobia
Patient surveys highlight injectables' 20-30% dropout rates due to needles; Foundayo's pill form could capture switchers and new entrants. Lilly's direct-to-patient platform hit 1M patients in 2025, and Medicare deals cap obesity drugs at $50/month out-of-pocket by July 2026. Early signals: Lilly's incretin doses exceeded goals, with 1.6x YoY production in H1 2025.
Competitive response? Novo counters with oral semaglutide (Rybelsus) but at lower doses, and pipeline bets like CagriSema (Phase 3 reads exciting but delayed). NVO's Q4 sales tables show injectable GLP-1 flat -2% CER, insulin declining -10%—vulnerable to oral disruption. Lilly's Q3 2025 revenue $17.6B (+54% YoY) vs. Novo's sputtering growth positions LLY to potentially double obesity market share.
| Quarterly Revenue (Latest) | LLY | YoY Growth | NVO (Obesity Care Q4 2025, DKK) | YoY CER |
|---|---|---|---|---|
| Q3/Q4 2025 | $17.6B / $19.3B | +54% | 22.4B | +11% |
Valuation Verdict: Buy the Geopolitical Dip
At 41.5x TTM P/E, Lilly trades rich but justified by 95% EPS growth and pipeline (orforglipron, Kisunla expansions). Novo's 10.1x looks cheap, but -26% YTD and guidance cuts signal deeper woes. Geopolitics? Transient—Lilly's US manufacturing investments top $50B since 2020, insulating supply.
Bullish on LLY: Foundayo's approval dip is a buying opportunity. Expect 20-30% uptake acceleration vs. injectables, pressuring Novo's moat. Monitor Q1 2026 launch metrics, Medicare patient adds, and Novo's CagriSema data. Risks: Pricing wars or supply snags, but Lilly's scale wins.